Literature DB >> 3118560

Effects of cromolyn in horses with chronic obstructive pulmonary disease.

L R Soma1, J Beech, N H Gerber.   

Abstract

The effect of disodium cromoglycate (cromolyn) in preventing the pulmonary dysfunction caused by the inhalation of barn and hay dust was studied in 5 horses with confirmed chronic obstructive pulmonary disease (COPD). The horses were studied before (Con) and after exposure to hay and dust allergens (Expos) and after pretreatment with cromolyn followed by exposure (Cr-Expos). There was a significant reduction in PaO2 from 86.8 +/- 8.3 to 73.1 +/- 8.8 when the horses were exposed to hay and dust allergens. The PaO2 after pretreatment with cromolyn and exposures was 78.1 +/- 5.5. There were no significant changes in PaCO2, FRC, pH and A-aDO2 when the Con, Expos, and Cr-Expos periods were compared. There were significant increases in VE from a control value of 77.9 +/- 18.2 to 128.7 +/- 55.1 and 133.7 +/- 17.1 L/min during the exposures, which was due primarily to increases in respiratory frequency. Respiratory dead space (VD/VT) increased from 0.55 +/- 0.10 to 0.71 +/- 0.07 and 0.65 +/- 0.05, and alveolar ventilation (VA) remained constant. Pulmonary resistance (RL) and transpulmonary pressure (Ptr) increased from a control of 0.77 +/- 0.28 cm H2O/L/sec and 7.73 +/- 3.38 cm H2O to 2.93 +/- 1.01 and 20.17 +/- 4.81 during the Expos period and tidal volume (VT) fell from 7.5 +/- 1.0 to 5.7 +/- 1.3 L. The pre-treatment with cromolyn before exposures significantly reduced the increase in RL and Ptr and returned VT to Con levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118560     DOI: 10.1007/bf00346192

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  30 in total

1.  COMPONENTS OF ALVEOLAR-ARTERIAL O2 DIFFERENCE IN NORMAL MAN.

Authors:  S M AYRES; A CRISCITIELLO; E GRABOVSKY
Journal:  J Appl Physiol       Date:  1964-01       Impact factor: 3.531

2.  The effect of cholinergic agents on a canine model of allergic asthma.

Authors:  R D Krell; L W Chakrin; J R Wardell
Journal:  J Allergy Clin Immunol       Date:  1976-07       Impact factor: 10.793

Review 3.  Pulmonary function testing in horses.

Authors:  R A Willoughby; W N McDonell
Journal:  Vet Clin North Am Large Anim Pract       Date:  1979-05

4.  Measurements of the dead space volume.

Authors:  C J Martin; S Das; A C Young
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-08

5.  Chronic pulmonary disease in the horse.

Authors:  H Gerger
Journal:  Equine Vet J       Date:  1973-01       Impact factor: 2.888

6.  Use of an analog on-line computer for the evaluation of pulmonary resistance and dynamic compliance in the anesthetized dog.

Authors:  R E Giles; M P Finkel; J Mazurowski
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-12

7.  Effect of changes of tidal volume on dead space in obstructive lung disease.

Authors:  J Read; J Lee
Journal:  J Appl Physiol       Date:  1969-01       Impact factor: 3.531

8.  External scintigraphy in evaluating delivery techniques of sodium cromolyn-[99mTc] diethylenetriaminepentacetic acid aerosol in the lungs of the horse.

Authors:  M C Theodorakis; C J Hillidge; R A Allhands
Journal:  J Pharm Sci       Date:  1983-05       Impact factor: 3.534

9.  Gas mixing within the acinus of the lung.

Authors:  L A Engel
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-03

10.  Naturally occurring emphysema, the fine gross and histopathologic counterpart of human emphysema.

Authors:  R F McLaughlin; D W Edwards
Journal:  Am Rev Respir Dis       Date:  1966-01
View more
  2 in total

1.  Evaluation of an in vitro degranulation challenge procedure for equine pulmonary mast cells.

Authors:  J E Hare; L Viel; P D Conlon; J S Marshall
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

Review 2.  A review of the pathophysiology of exercise-induced pulmonary haemorrhage in the equine athlete.

Authors:  L L Donaldson
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.